Skip to main content

Table 4 Study 3—Electrophysiology of compound action potential (CAP) waveforms (Fig. 6). Two-way ANOVA results with Holm-Sidak post hoc test and Cohen’s d effect size

From: Acute axon damage and demyelination are mitigated by 4-aminopyridine (4-AP) therapy after experimental traumatic brain injury

Outcome measure

F (DFn, DFd); p-value

Adjusted p-value

Cohen’s d effect size

N1 conduction velocity

Interaction:

F1,43 = 0.05412, p = 0.8171

Injury:

F1,43 = 26.20, p < 0.0001

Drug:

F1,43 = 1.056, p = 0.3098

sham veh vs TBI veh:

p = 0.0067

sham 4-AP vs TBI 4-AP:

p = 0.0016

TBI veh vs TBI 4-AP:

ns, p = 0.6182

sham veh vs TBI veh:

d = 1.646

sham 4-AP vs TBI 4-AP:

d = 1.405

TBI veh vs TBI 4-AP:

d = 0.286

N2 conduction velocity

Interaction:

F1,43 = 0.2463, p = 0.6222

Injury:

F1,43 = 6.691, p = 0.0132

Drug:

F1,43 = 0.9846, p = 0.3266

sham veh vs TBI veh:

ns, p = 0.1860

sham 4-AP vs TBI 4-AP:

ns, p = 0.4377

TBI veh vs TBI 4-AP:

ns, p = 0.5970

sham veh vs TBI veh:

d = 0.945

sham 4-AP vs TBI 4-AP:

d = 0.582

TBI veh vs TBI 4-AP:

d = 0.577

N2 width

at half-maximum

Interaction:

F1,43 = 0.1562, p = 0.6947

Injury:

F1,43 = 7.827, p = 0.0077

Drug:

F1,43 = 0.1402, p = 0.7099

sham veh vs TBI veh:

ns, p = 0.1601

sham 4-AP vs TBI 4-AP:

ns, p = 0.3032

TBI veh vs TBI 4-AP:

ns, p = 0.9883

sham veh vs TBI veh:

d = 1.003

sham 4-AP vs TBI 4-AP:

d = 0.675

TBI veh vs TBI 4-AP:

d = 0.008

N2 peak to recovery

Interaction:

F1,43 = 2.797, p = 0.1017

Injury:

F1,43 = 5.211, p = 0.0275

Drug:

F1,43 = 0.08605, p = 0.7707

sham veh vs TBI veh:

ns, p = 0.0560

sham 4-AP vs TBI 4-AP:

ns, p = 0.6579

TBI veh vs TBI 4-AP:

ns, p = 0.5517

sham veh vs TBI veh:

d = 1.240

sham 4-AP vs TBI 4-AP:

d = 0.171

TBI veh vs TBI 4-AP:

d = 0.365

  1. veh Saline vehicle control; ns: non-significant (p > 0.05). Sham veh vs sham 4-AP ns for each measure (p > 0.5 or higher)